ANGPTL3

Assets acting on this target.

Class
ANGPTL3 inhibitor

ANGPTL3 (angiopoietin-like 3) is a liver-secreted protein that inhibits two enzymes central to lipid processing: lipoprotein lipase and endothelial lipase. By restraining these enzymes, ANGPTL3 normally limits the breakdown of triglyceride-rich lipoproteins and the metabolism of certain lipoprotein particles in the bloodstream. When ANGPTL3 is blocked or removed, lipoprotein lipase activity increases, accelerating clearance of triglycerides and, through downstream effects on lipoprotein particle metabolism, lowering LDL cholesterol as well. This makes ANGPTL3 an attractive target for lowering multiple types of atherogenic lipids simultaneously, which is relevant in severe inherited disorders of cholesterol and triglyceride metabolism, as well as in broader cardiovascular risk reduction where standard lipid-lowering approaches are insufficient or not tolerated. Notably, individuals with naturally occurring loss-of-function mutations in ANGPTL3 have markedly reduced lipid levels and do not appear to suffer obvious harm, which has supported confidence in pursuing this target pharmacologically. A range of modalities has been developed against ANGPTL3, including antibodies that neutralize the circulating protein, small interfering RNA and gene-editing approaches that reduce its production in the liver, and small molecules, reflecting different strategies for achieving durable suppression of this pathway.

By indication

Related mechanisms

ANGPTL3 drugs compared

9 drugs, stage by indication
9 drugs acting on ANGPTL3: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
EvinacumabEvkeezaRegeneron Pharmaceuticals, Ultragenyx Pharmaceutical Inc.monoclonal antibodyApprovedApproved in Homozygous Familial Hypercholesterolemia
SHR-1918Jiangsu Hengrui Pharmaceuticalsmonoclonal antibodyPhase 3Phase 3 in Homozygous Familial Hypercholesterolemia
ALN-ANG3Regeneron PharmaceuticalsRNAi (siRNA)Phase 2Phase 2 in Chronic Kidney Disease; Phase 1 in Atherosclerotic Cardiovascular Disease
BW-00112Shanghai Argo BiopharmaceuticalRNAi (siRNA)Phase 2Phase 2 in Hypertriglyceridemia
EDP167Edding Genor Group Holdings Limited, Eddingpharm (Zhuhai) Co., Ltd.RNAi (siRNA)Phase 2Phase 2 in Atherosclerotic Cardiovascular Disease; Phase 2 in Hypertriglyceridemia
SolbinsiranEli LillyRNAi (siRNA)Phase 2Phase 2 in Atherosclerotic Cardiovascular Disease; Phase 2 in Severe Hypertriglyceridemia
SYH2070CSPC Pharmaceutical GroupRNAi (siRNA)Phase 2Phase 2 in Atherosclerotic Cardiovascular Disease
CTX310CRISPR Therapeuticsgene editing (CRISPR-Cas9)Phase 1Phase 1 in Atherosclerotic Cardiovascular Disease; Phase 1 in Severe Hypertriglyceridemia
NNC0491-6075Novo Nordiskmonoclonal antibodyPhase 1Phase 1 in Atherosclerotic Cardiovascular Disease

← all mechanisms